Viatris Inc. Q3 2025 Earnings Recap

Viatris reported a robust Q3 2025, with solid revenue growth and an increase in full-year guidance, bolstered by strong commercial execution and advancements in its product pipeline.

Key Takeaways

• Achieved 1% operational revenue growth (excluding Indore), consistent with expectations, driven by strong performance in Europe and emerging markets.
• Raised full-year guidance for total revenues, adjusted EBITDA, and adjusted EPS due to positive momentum within the business.
• Significant progress in pipeline development, including a forthcoming NDA for fast-acting meloxicam and advancements in Phase III programs for cenerimod and selatogrel.
• Returned over $920 million to shareholders year-to-date, including $500 million in share repurchases, on track to exceed $1 billion in capital returns for the year.
• Strategic review targeting operational efficiencies and growth reinvestment is underway, with opportunities for meaningful cost savings identified.